Preclinical evaluation of MORAb-009,a chimeric antibody targeting tumor-associated mesothelin

Cancer immunity

Martin D. Phillips⁵  Wolfgang Ebel⁵  Sara Jacob⁵  Jingli Zhang⁴  Maria Moreno²  Qimin Chao⁵  Elizabeth M. Jaffee¹  Philip M. Sass⁵  Lester Gibbs⁵  Rina Patel⁵  Ira Pastan⁴  Nicholas C. Nicolaides⁵  J. Bradford Kline⁵  Howard Turchin⁵  Christine Iacobuzio-Donahue³  Raffit Hassan⁴  Luigi Grasso⁵  Eric L. Routhier⁵  Shiyama Mudali³ 

[1] Department of Oncology, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USADepartment of Oncology, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USADepartment of Oncology, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USA;Obstetrics and Gynecology, VU MedicalCentre, Amsterdam, TheNetherlandsObstetrics and Gynecology, VU MedicalCentre, Amsterdam, TheNetherlandsObstetrics and Gynecology, VU MedicalCentre, Amsterdam, TheNetherlands;Drug Development Program, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USADrug Development Program, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USADrug Development Program, The Sol GoldmanPancreatic Cancer Research Center, Johns Hopkins University, Baltimore,MD, USA;Laboratory of Molecular Biology, NationalCancer Institute, Bethesda, MD, USALaboratory of Molecular Biology, NationalCancer Institute, Bethesda, MD, USALaboratory of Molecular Biology, NationalCancer Institute, Bethesda, MD, USA;Morphotek Inc., Exton,PA, USAMorphotek Inc., Exton,PA, USAMorphotek Inc., Exton,PA, USA

关键词: preclinical drug evaluation;    monoclonal antibody;    mesothelin;    antibody-dependentcellular cytotoxicity;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown